# Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia

> **NCT04230239** · PHASE2 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 59 (actual)

## Conditions studied

- Newly Diagnosed Secondary or High Risk AML

## Interventions

- **DRUG:** CPX-351

## Key facts

- **NCT ID:** NCT04230239
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-26
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-08-11
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04230239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04230239, "Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04230239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*